Muedzo Unotanga paMonotherapy yeSarudzo Yepamberi kana Metastatic Solid Tumors

Jazz Pharmaceuticals plc nhasi yazivisa murwere wekutanga akanyoreswa muEMERGE-201, Phase 2 kiriniki yekuyedza inoongorora kuchengetedzeka uye kushanda kweZepzelca® (lurbinectedin) se monotherapy mumapoka matatu evarwere vane advanced urothelial carcinoma, hombe cell neuroendocrine carcinoma ye mapapu, kana homologous recombination deficient (HRD) mapundu akafambira mberi pachirongwa chine platinum. EMERGE-201 ichanyanya kuongorora huwandu hwemhinduro dzevarwere (ORR), maererano neResponse Evaluation Criteria in Solid Tumors (RECIST).

"Kunyangwe nekufambira mberi nekukurumidza kwehunyanzvi hwekurapa uye kuchengetwa kwemhando dzemabundu mumakore gumi apfuura, kuchine varwere vazhinji vachiri kutarisana nezvido zvisina kufanira uye vachiona mutoro wakakura wehurwere nekufa," akadaro Arielle Heeke, MD, mazamu. chiremba oncologist paLevine Cancer Institute uye muongorori wekutanga muEMERGE-201 muedzo. "Neye EMERGE-201 muyedzo urikuenderera mberi, isu tinotarisira kuona zvinogona kuitika muchipatara cheZepzelca pamakenza akasimba emamota, anosanganisira kenza dzeHRD, ane mashoma nzira dzekurapa dzakabvumidzwa kunze kwechinyakare chemotherapy. Muyedzo uchaongorora kana kurapwa uku kuchigona kuita kuti bundu ripindurwe zvichibva pazviri biology yeaya magomarara uye nzira yeZepzelca yemaitiro. "

"Kutanga kuyedza uku chiitiko chinonakidza chechirongwa cheZepzelca chekuvandudza kiriniki, apo tiri kutsvaga kuongorora kushanda kwayo kwekiriniki kupfuura kurapa gomarara remapapu," akadaro Rob Iannone, MD, MSCE, mutevedzeri wemutungamiri wenyika, mukuru wepasi rose wezvekutsvagisa nekusimudzira Jazz. Pharmaceuticals. "Tichifunga Zepzelca inokonzeresa kuitika kwezviitiko zvinogona kukanganisa basa reDNA inosunga mapuroteni - kusanganisira zvinyorwa uye nzira dzekugadzirisa DNA - isu tinotarisira kuongorora chiitiko cheZepzelca mukuwedzera kuoma-kurapa kenza uko mutyairi oncogenes anonyorwa uye kugadzirisa DNA. maitiro haashande, senge urothelial carcinoma, hombe cell neuroendocrine carcinoma yemapapu uye HRD-positive tumors.

EMERGE-201 Tsanangudzo Yekuedza

EMERGE-201 muyedzo weChikamu chechipiri, wakawanda, wakavhurika-label wakagadzirirwa kuongorora kuchengetedzeka uye kushanda kweZepzelca se monotherapy mumapoka matatu evarwere vane mamota akasimba, vanozogamuchira 2 mg/m3.2 doses yeZepzelca intravenously pazuva rekutanga. kutenderera kwemavhiki matatu ega ega, kusvika kwasimbiswa kukura kwechirwere. Mapoka matatu aya ndeaya: varwere vane advanced urothelial carcinoma, hombe cell neuroendocrine carcinoma yemapapu, kana HRD tumors vakafambira mberi pachirongwa chine platinum.

Chinangwa chikuru ndechekuona kugona kweZepzelca kuvandudza mhedzisiro yevarwere, sekuyerwa neORR. Mamiriro ekupedzisira echipiri anosanganisira muongorori-akaongororwa kufambira mberi kwemahara, nguva-yekupindura, nguva yekupindura, uye chirwere chekudzora chiyero sezvakaongororwa neRECIST, pamwe nekupona kwese kwevatori vechikamu vanobatwa neZepzelca. Kutongwa uku kunotsigirwa uye kuri kuitwa nekambani yeJazz Pharmaceuticals.

Dzinoda kusvika masaiti makumi maviri muUS achatora chikamu muyedzo iyi.